Urothelial cancer approval for Gemzar in Japan
This article was originally published in Scrip
Lilly's chemotherapy Gemzar (gemcitabine) has been approved in Japan for the additional indication of urothelial cancer. The product is already approved in this market for non-small cell lung, pancreatic and biliary tract cancers and is in local development for breast cancer. Urothelial cancer affects an estimated 16,000 people in the country, mostly older men, the company's Japanese subsidiary noted. Total sales of Gemzar in Japan last year were around ¥15 billion ($157.7 million).